83 related articles for article (PubMed ID: 26090600)
1. Production and Characterization of New Anti-HER2 Monoclonal Antibodies.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):213-21. PubMed ID: 26090600
[TBL] [Abstract][Full Text] [Related]
2. Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.
Mahdavi M; Keyhanfar M; Jafarian A; Mohabatkar H; Rabbani M
Tumour Biol; 2014 Dec; 35(12):12049-57. PubMed ID: 25142233
[TBL] [Abstract][Full Text] [Related]
3. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines.
Manijeh M; Mehrnaz K; Violaine M; Hassan M; Abbas J; Mohammad R
Asian Pac J Cancer Prev; 2013; 14(10):5973-81. PubMed ID: 24289611
[TBL] [Abstract][Full Text] [Related]
4. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
[TBL] [Abstract][Full Text] [Related]
5. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of new HER2 monoclonal antibodies.
Vasconcellos FA; Aleixo PB; Stone SC; Conceição FR; Dellagostin OA; Aleixo JA
Acta Histochem; 2013 Apr; 115(3):240-4. PubMed ID: 22901624
[TBL] [Abstract][Full Text] [Related]
8. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
Yip YL; Smith G; Koch J; Dübel S; Ward RL
J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
[TBL] [Abstract][Full Text] [Related]
9. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein.
Chua CL; Chan YF; Sam IC
J Virol Methods; 2014 Jan; 195():126-33. PubMed ID: 24134938
[TBL] [Abstract][Full Text] [Related]
11. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
[TBL] [Abstract][Full Text] [Related]
12. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
Verma B; Hawkins OE; Neethling FA; Caseltine SL; Largo SR; Hildebrand WH; Weidanz JA
Cancer Immunol Immunother; 2010 Apr; 59(4):563-73. PubMed ID: 19779714
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
[TBL] [Abstract][Full Text] [Related]
14. Linear and conformational B cell epitope prediction of the HER 2 ECD-subdomain III by in silico methods.
Mahdavi M; Mohabatkar H; Keyhanfar M; Dehkordi AJ; Rabbani M
Asian Pac J Cancer Prev; 2012; 13(7):3053-9. PubMed ID: 22994709
[TBL] [Abstract][Full Text] [Related]
15. Protection against measles virus-induced encephalitis by anti-mimotope antibodies: the role of antibody affinity.
Olszewska W; Obeid OE; Steward MW
Virology; 2000 Jun; 272(1):98-105. PubMed ID: 10873752
[TBL] [Abstract][Full Text] [Related]
16. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
[TBL] [Abstract][Full Text] [Related]
17. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities.
Dakappagari NK; Lute KD; Rawale S; Steele JT; Allen SD; Phillips G; Reilly RT; Kaumaya PT
J Biol Chem; 2005 Jan; 280(1):54-63. PubMed ID: 15507452
[TBL] [Abstract][Full Text] [Related]
18. A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK; Pyles J; Parihar R; Carson WE; Young DC; Kaumaya PT
J Immunol; 2003 Apr; 170(8):4242-53. PubMed ID: 12682258
[TBL] [Abstract][Full Text] [Related]
19. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.
Kaumaya PT; Foy KC; Garrett J; Rawale SV; Vicari D; Thurmond JM; Lamb T; Mani A; Kane Y; Balint CR; Chalupa D; Otterson GA; Shapiro CL; Fowler JM; Grever MR; Bekaii-Saab TS; Carson WE
J Clin Oncol; 2009 Nov; 27(31):5270-7. PubMed ID: 19752336
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of a new chimeric antibody against HER2.
Amiri MM; Jeddi-Tehrani M; Kazemi T; Bahadori M; Maddah M; Hojjat-Farsangi M; Khoshnoodi J; Rabbani H; Shokri F
Immunotherapy; 2013 Jul; 5(7):703-15. PubMed ID: 23829622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
